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igniﬁcantly different concentrations of cytokines, chemokines and growth factors
healthy and osteoarthritic synovial ﬂuid (average  sd; pg/ml). #p<0.001 and
p<0.05
Healthy
(average 
sd; pg/ml)
OA (average
 sd; pg/ml)
P-value
Eotaxin 22.4  21.4 8.0  18.8 *0.02
G-CSF 90.1  95.4 22.4  15.0 *0.03
IL-6 57.0  112.2 186.1  224.1 #0.001
IP-10 521.5  561.2 1073.6  999.0 #0.001
MDC 55.6  24.4 210.1  87.4 #0.001
MIP-1a 4.5  1.2 16.5  28.2 *0.05
MIP-1ß 12.7  10.6 35.0  44.7 *0.04
PDGF-AA 1.5  3.0 122.6  89.3 #0.001
RANTES 31.7  48.3 762.9  871.9 #0.001
sCD40L 1.0  2.3 29.2  42.3 *0.005
Leptin 837.3  1115 3008.1  3770 *0.01
IL-13 nd 18.1  39.5 *0.01
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S79respectively), that persisted for sHA and uCTX-II after adjustment for age,
gender and BMI (stand betas 0.113, P¼0.003 and 0.129, P¼0.000, respec-
tively). Only cartilage marker combinations showed stronger associations
with baseline summed K&L grades than individual biomarkers (stand beta
0.150, P¼0.000 for uCTX-II+sCOMP+PIIANP+CS846 combination, after
adjustment).
Associations with AUC of the summed K&L score were statistically signif-
icant for uCTX-II, sCOMP, sPIIANP, and sCS846 (stand betas 0.089-0.133,
P<0.018) and persisted after adjustment for age, gender, BMI, and baseline
summed K&L score for sCOMP only (stand beta 0.105, P¼0.005). Stronger
associations were observed for cartilage and synovial combinations (stand
beta 0.128, P¼0.001 for uCTXII+sCOMP+sPIIANP+sCS846, and stand beta
0.110, P¼0.003 for sCOMP+sPIIINP).
Conclusions: Associations with burden and progression of (very) early
knee and hip OAwere observed for cartilage and synovial biomarkers. The
low grade of the associations may be due to limitations of biomarkers as
well as radiography in reﬂecting disease in OA, especially in early-stage
disease. Associations may be stronger at 10-year follow-up and/or when
using more sensitive measures of individual radiographic OA features (e.g.
osteophytes, joint space narrowing, etc). Nevertheless, together with
literature data these results indicate that the search for biomarkers for
(very) early OA should be primarily aimed at (combinations of) cartilage
and synovial metabolism.
This study was funded by CHECK (Cohort Hip & Cohort Knee), an initiative
of the Dutch Arthritis Association.
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OSTEOARTHRITIS BIOMARKERS IN HUMAN SERUM BY CHEMICAL
DEPLETION COUPLED TO TWO DIMENSIONAL DIFFERENCE IN GEL
ELECTROPHORESIS
C. Fernández-Costa 1, V. Calamia 1, J. Capelo 2, C. Ruiz-Romero 1,
F.J. Blanco 1. 1 INIBIC-CHUAC. Proteomic Group. ProteoRed/ISCIII.
Rheumatology Div., A Coruña, SPAIN; 2BIOSCOPE Group, Physical Chemistry
Dept., Sci. Facultaty, Univ. of Vigo at Ourense Campus, Ourense, SPAIN
Purpose: The aim of this study is to search for osteoarthritis (OA)
biomarkers in human serum using a novel chemical sequential depletion
method combined with two dimensional difference in-gel electrophoresis
(2D-DIGE) analyses.
Methods: The serum samples were obtained from 20 OA pacientes and 20
non-symptomatic controls. Samples were grouped into four pools of 10
samples each. The pools were subjected to a chemical sequential depletion
protocol involving two precipitation steps, ﬁrst with DTT and then with
ACN, to reduce the high dynamic range of the proteins. Then, the proteo-
mics comparison between OA and control sera was performed across four
DIGE gels. Samples from control and OA pools were labeled with Cy3 or
Cy5 dyes, mixed by pairs and co-resolved by two-dimensional gel elec-
trophoresis using a pool of all samples labeled with Cy2 as internal stan-
dard. The gels were imaged using a DIGE Imager scanner, and quantitative
image analysis was performed using Same Spots software. For protein
identiﬁcation, gel spots were digested by in-gel enzymatic digestion
accelerated with ultrasounds. Then, peptides were analyzed by mass
spectrometry (MALDI-TOF/TOF) and identiﬁed using Mascot with Swis-
sProt knowledgebase. Veriﬁcation of the alteration of SAA and HPT was
performed by immunoblotting.
Results: We report the combination of a novel chemical sequential
depletion method combined with 2D-DIGE for the search of OA
biomarkers. An average of 210 protein spots were detected and matched
on the gel images. The differential analysis resulted in 42 spots signiﬁ-
cantly and reproducibly altered between OA and control samples, 29
increased and 17 decreased. These 45 spots corresponded to 14 different
proteins, many of them related with lipid transport, immune response or
protein binding. We identiﬁed a spot corresponding to a serum amyloid A
protein form (SAA), which was decreased in OA sera when compared to
control. SAA is a major acute phase reactant implicated in the pathogenesis
of rheumatoid arthritis, however, the role of SAA in OA has been poorly
investigated. We also detected two spots corresponding to haptoglobin
precursor (HPT) that exhibited an opposite alteration in OA sera when
compared to control. HPT precursor is an N-linked glycoprotein known to
be cleaved into two chains, alpha and beta, which combine with freeplasma hemoglobin and contribute to the maintenance of cellular iron
homeostasis. Interestingly, HPT beta chain was increased in OA sera whilst
HPT alpha chain was decreased in OA sera when compared to control.
Western blot analyses were performed to conﬁrm these results. The
detection of modulated SAA and HPT protein forms in this work highlight
the usefulness of 2D gel-based approaches for characterizing disease-
speciﬁc patterns of protein modiﬁcations, which are impossible to obtain
from peptide/MS-based proteomic strategies.
Conclusions: We were able to identify 15 protein forms altered in the
disease, corresponding to 14 different proteins. The chemical sequential
depletion coupled to a DIGE-based quantitative proteomic analysis is
useful for protein biomarker discovery. We provide a list of potential OA
biomarker candidates that might be the subject of further validation
studies.
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A DESCRIPTIVE STUDY OF SYNOVIAL FLUID CHANGES IN CYTOKINE,
CHEMOKINE AND GROWTH FACTOR LEVELS BETWEEN
OSTEOARTHRITIS PATIENTS AND HEALTHY DONORS.
M. Beekhuizen 1, L. Gierman 2, L.B. Creemers 1, W.J. Dhert 1, T.W.
Huizinga 3, G.J. van Osch 4, A.-M. Zuurmond 2. 1UMC Utrecht, Utrecht,
NETHERLANDS; 2 TNO, Leiden, NETHERLANDS; 3 LUMC, Leiden,
NETHERLANDS; 4 Erasmus MC, Rotterdam, NETHERLANDS
Purpose: Many studies have shown differences between the healthy and
osteoarthritic (OA) joint environment. These studies are mainly based on
a limited set of cytokines, chemokines or growth factors. A comprehensive
proﬁle of these kind of mediators for OA patients could potentially
contribute to the search for new biomarkers or biomarker proﬁles. In the
current study, we analysed 49 soluble mediators in synovial ﬂuid (SF) in
order to examine differences in the healthy and OA joint environment
proﬁle.
Methods: SF was obtained from donors with macroscopically
healthy knee joints (post-mortem material; n¼16) and from OA
patients (total knee arthroplasy for OA; n¼18). All samples were
analyzed for a set of 49 different cytokines, chemokines and growth
factors using multiplex ELISA assays. A non-parametric Mann-Whit-
ney U test was used to determine signiﬁcant differences. Signiﬁcance
was set at p<0.001.
Results: The majority of the soluble mediators could be detected in both
healthy and OA SF. IL-6, IP-10, MDC, PDGF-AA and RANTES were signiﬁ-
cantly increased in OA compared to healthy SF (Table 1.; p<0.001). Leptin,
IL-13, MIP1-a, MIP1-b, sCD-40L were also increased in OA compared to
healthy SF, however less signiﬁcant (p<0.05). In contrast, eotaxin and G-
CSF were decreased in OA synovial ﬂuid (p<0.05). The levels of anabolic
factors such as FGF-2 and TGF-ß were not different between healthy and
OA SF samples.T
S
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*
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cytokines, chemokines and growth factors present in the OA and the
healthy joint environment. Increased soluble mediators, such as IL-6, IP-10,
MDC and RANTES, indicate the involvement of a catabolic process in OA.
This biomarker proﬁle might be useful to distinguish OA patients from
healthy donors, however needs to be validated in future experiments.
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A NEW SANDWICH BIOMARKER ASSAY FOR CARTILAGE TYPE II
COLLAGEN CAN DISCRIMINATE BETWEEN NO OSTEOARTHRITIS (OA),
PRE-RADIOGRAPHIC AND RADIOGRAPHIC KNEE OA IN HUMAN URINE.
N. Ha 1, S. Bourdon 1, E.C. Sayre 2,3, A.R. Poole 4, A. Thorne 2,5, H. Wong 2,5,
J. Singer 2,6, J. Kopec 2,3, J.M. Esdaile 2,3, A. Guermazi 7, N. Savvakis 8,
J. Cibere 2,3. 1 IBEX Pharmaceuticals Inc., Montreal, QC, CANADA; 2Univ. of
British Columbia, Vancouver, BC, CANADA; 3Arthritis Res. Ctr. of Canada,
Vancouver, BC, CANADA; 4McGill Univ., Montreal, QC, CANADA; 5Canadian
HIV Trials Network, Vancouver, BC, CANADA; 6Ctr. for Hlth.Evaluation and
Outcome Sci., Vancouver, BC, CANADA; 7Boston Univ. Med. Ctr., Boston,
MA; 8Vancouver Gen. Hosp., Vancouver, BC, CANADA
Purpose: Molecular biomarkers, especially those that detect cleavage of
cartilage type II collagen, offer the potential to detect early pre-radio-
graphic osteoarthritis (PROA) and radiographic OA (ROA). Increased
type II collagen cleavage by collagenases is a well-established feature in
OA knee articular cartilage. Yet existing assays have exhibited limited
ability to discriminate between these patient populations and those
without OA. By focusing on a 45 mer collagenase-generated peptide of
type II collagen found in increased amounts in urine of OA patients
(Nemirovskiy et al, 2007), a new assay has been developed that can
discriminate knee PROA and knee ROA from subjects with no detectable
OA (NoOA) on magnetic resonance imaging (MRI). Initial encouraging
results are presented here.
Methods: The newly developed sandwich assay for urine (IB-C2C-
HUSATM) detects the type II collagen speciﬁc C-terminus of the 3/4 piece
generated by collagenase and an intrachain epitope within 45 residues of
this cleavage site. This was compared to an existing competitive inhibition
assay (C2C ELISA) that also detects this cleavage site neoepitope in type II
collagen alpha-chains and any other alpha-chain fragments containing this
neoepitope. Assay results were expressed as pg per mmol creatinine. Urine
samples from the population-based Model for the Diagnosis of Early Knee
Osteoarthritis (MoDEKO) cohort were analyzed. The unique MoDEKO
cohort consists of subjects with knee pain, age 40 to 79, classiﬁed based on
knee MRI and x-ray (34 NoOA; 120 PROA and 98 ROA_sample-weighted
counts). Data were analyzed for differences between OA subgroups using
descriptive statistics. Multinomial logistic regression analysis was per-
formed to evaluate the associations between biomarkers and radio-
graphically/MRI deﬁned OA subgroups vs. NoOA, reported as odds ratios
(ORs) and 95% conﬁdence intervals (CI) after log-transformation and
adjustment for age, gender and BMI. All analyses were sample-weighted.
Results: Results for the C2C ELISA inhibition assay revealed no ability to
discriminate between the different groups in urine (Fig.1). In contrast, the
IB-C2C-HUSATM sandwich assay revealed the presence of progressively
higher concentrations of the cleavage neoepitope in PROA and ROA groups
compared to the NoOA group (Fig.1). Multinomial logistic regression
results revealed that the new urine assay could signiﬁcantly predict the
three groups (overall p <0.001): OR 2.90 (95% CI 1.64, 5.13) for ROA vs.
NoOA, OR 1.55 (95% CI 0.95, 2.50) for PROA vs. NoOA and OR 1.88 (95% CI
1.27, 2.77) for ROA vs. PROA. Interestingly, this discrimination was often
stronger when urine data were not corrected for creatinine: OR 3.97 (2.03,
7.78) for ROA vs. NoOA ; OR 2.30 (1.22, 4.32) for PROA vs. NoOA and OR 1.73
(1.23, 2.43) for ROA vs. PROA.
Conclusions: Our results demonstrate the ability of this new urine-speciﬁc
sandwich assay to discriminate between NoOA, PROA and ROA in amanner
not previously possible with the original C2C inhibition assay. It also
provides further evidence to suggest that the 45mer alpha-chain fragment
of type II collagen, that contains the collagenase cleavage site, is generated
in increased amounts in knee OA and can be selectively detected in urine.
This new biomarker assay may be of value in studying disease onset,
progression and treatment in OA.Ă
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MEASUREMENTS OF URINARY COLL2-1NO2 IS PREDICTIF OF JOINT
SPACE NARROWING IN KNEE OSTEOARTHRITIS
Y. Henrotin 1, V. Kraus 2, K.D. Brandt 3, S.A. Mazzuca 3, J. Huebner 2,
B. Boulanger 4, M. Deberg 5. 1Bone and Cartilage Res. Unit, Liège, Belgium;
2Duke Univ. Med. Ctr., Durham, NC; 3Univ. Sch. of Med., Indianapolis, IN;
4Arlenda SA, Liège, Belgium; 5Artialis SA, Liège, BelgiumPurpose: To evaluate the predictive value of Coll2-1NO2, a biochemical
marker of inﬂammation-related cartilage degradation, for radiographic
knee osteoarthritis (OA) progression. Coll2-1NO2 [HRGY(NO2)PGLDG], is
the nitrated from of Coll2-1 (HRGYPGLDG), a denaturation epitope of the
type II collagen molecule.
Methods: Two OA populations were studied: population 1 was composed
by 135 obese men andwomen aged 45 to 64 years with mild andmoderate
knee OA (presence of osteophytes and a minimum joint space width  2
mm in themedial compartment); population 2 included 182 obesewomen
with unilateral radiographic knee OA (K&L II or III) aged 45 to 64 years from
the placebo arm of the doxycycline study (Brandt et al., 2004). For both
populations, quantitative estimates of changes in joint space width (JSW)
in the medial tibiofemoral compartment were obtained from ﬂuoroscop-
ically assisted semi-ﬂexed AP radiographs performed at baseline,16 and 30
months. The creatinine-adjusted urinary Coll2-1NO2 (uColl2-1NO2)
concentrationwas measured on samples obtained at baseline, after 16 and
30 months for the patients from population 1 and at baseline and after 6,
12, 18, 24 and 30 months for the patients from population 2. Patients
showing a decrease of JSW  0.5 mm over 30 months follow-up were
designated radiographic progressors. The comparison of progressor and
nonprogressor patients at inclusion was performed by an unpaired t-test.
The results were expressed as medians (minimum and maximum). The
ability of biomarker to predict radiographic progression of knee osteoar-
thritis was evaluated by logistic regression analysis. The covariates in the
model are uColl2-1NO2 at baseline and the change over 16 months of
uColl2-1NO2.
